REPLIGEN CORPRGEN

時価総額

$88.5億

PER

バイオ医薬向けバイオプロセス機器・試薬の最大手。フィルトレーション、クロマトグラフィー、プロセス分析、単回使用消耗品（XCell ATF等）を展開。2024年のTantti買収（約7,480万ドル）や2023年のMetenova買収を実施。北米・欧州・アジア太平洋地域で展開。

概要財務

サマリーテーブルに戻る

	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net income	-1,612,625	14	16	8	9	12	28	17	21	60	128	186	42	-26
Inventory step-up charges	-	-	-	-	-	-	-	-	-	-	2	-	1	-
Depreciation and amortization	1	4	3	4	5	5	11	16	21	27	38	51	68	70
Amortization of Debt Discount (Premium)	-	-	-	-	-	2	4	4	8	-	12	2	2	16
Stock-based compensation	730,136	1	1	2	4	5	7	10	13	17	28	27	26	48
Deferred income taxes, net	15,744	-3,143,268	3	295,095	-0	-4	-25	0	-1	-4	7	-1	2	-17
Contingent consideration	-	-	-	2	4	3	-	-	-	-	-	-	-31	3
Non-cash interest income	-	-	-	-	-	-	-	-	-	-	-	-	2	-
Loss on extinguishment of debt	-	-	-	-	-	-	-	-	-6	-	-0	-	-13	-
Loss on fixed asset abandonment	-	-	-	-	-	0	-	-	-	-	-	-	-	-4
Operating lease right of use asset amortization	-	-	-	-	-	-	-	-	5	-4	4	25	-14	-17
Other	-	-	-	-	-	-	-	0	-1	-0	-1	0	-1	0
Accounts receivable	-3,551,969	1	773,954	2	4	3	7	6	8	21	47	4	3	14
Inventories	870,252	-2,734,239	625,895	860,124	6	6	-1	4	9	29	90	57	-41	-57
Prepaid expenses and other assets	190,007	-30,266	-57,604	820,060	0	-1	1	2	1	5	10	-2	13	-2
Other assets	-	-	-	-	-	-	-	-	-	-	-0	0	0	-0
Accounts payable	247,222	1	-733,728	2	3	-2	1	2	1	2	20	-8	-10	13
Accrued expenses	243,182	2	1	-2,489,152	-2	-4	-2	-1	13	1	23	-2	-28	6
Operating lease liability	-	-	-	-	-	-	-	-	-	-	-	29	-9	-8
Long-term liabilities	-	-	-	-1,036,082	-	-	1	-0	-0	1	-1	1	0	5
Total cash provided by operating activities	2	13	26	-	-	-	-	33	67	63	119	172	114	175
Purchase of marketable securities held to maturity	-	-	-	-	-	-	-	-	-	-	-	100	-	-
Redemption of marketable securities	46	43	29	35	28	23	20	-	-	-	-	-	102	-
Additions to capitalized software costs	-	-	-	-	-	-	-	2	5	4	4	4	3	4
Acquisitions, net of cash acquired	-	-	-	-	-	-	-	-	-	175	150	-	187	55
Purchases of property, plant and equipment	575,455	1	5	6	3	4	5	11	19	22	67	85	36	26
Purchase of intellectual property	-	-	-	-	-	-	-	-	-	-	-	45	-	3
Other investing activities	-	-	-	-	-	-	-	-	-	-	-	-0	-0	-1
Total cash used in investing activities	-5,010,610	3	-17,906,289	-	-	-	-	-14	-205	-201	-221	-233	-123	-86
Repurchase of common stock	330,867	-	-	-	-	-	-	-	-	-	-	-	14	-
Proceeds from Convertible Debt	-	-	-	-	-	111	-	-	278	-	-	-	290	-
Proceeds from Stock Options Exercised	25	1	2	2	1	2	2	3	1	8	4	4	1	4
Payment of debt issuance costs	-	-	-	-	-	-	-	-	-	-	-	-	7	-
Payment of tax withholding obligation on vesting of restricted stock units	-	-	-	-	-	-	-	-	0	0	3	17	13	10
Payment of earnout consideration	-	-	-	-	-	-	-	-	-	-	-	-	7	7
Repayment of Convertible Senior Notes	-	-	-	-	-	-	-	0	115	-	0	0	-	70
Other financing activities	-	-	-	-	-	-	-	-	-	-	-	-	-0	-
Total cash (used in) provided by financing activities	-330,842	1	3	-	-	-	-	3	485	306	1	-13	249	-83
Effect of exchange rate changes on cash and cash equivalents	-	-	-	-	-	-	-	-	-	-	-	-6	-12	-0
Net increase (decrease) in cash and cash equivalents	-	-	-	-	-	-	-	-	344	180	-113	-80	228	6
Income taxes paid	-	-	-	-	-	-	-	4	7	10	17	34	27	19
Interest paid	-	-	-	-	-	-	-	2	1	1	1	1	1	6
Assets acquired under operating leases	-	-	-	-	-	-	-	-	-	-	-	-	4	38
Stock Issued	-	-	-	-	-	14	-	-	-	-	-	-	14	-
Fair value of shares of common stock issued for contingent consideration earnouts	-	-	-	-	-	-	-	-	-	-	-	-	7	6
Acquisition date fair value of contingent consideration earnouts	-	-	-	-	-	-	-	-	-	-	-	-	7	20
Notes Issued	-	-	-	-	-	-	-	-	-	-	-	-	42	-
Extinguished 2019 Notes	-	-	-	-	-	-	-	-	-	-	-	-	30	-